Endocrine therapies in breast and prostate cancer
著者
書誌事項
Endocrine therapies in breast and prostate cancer
(Cancer treatment and research)
Nijhoff , Distributors for the U.S. and Canada, Kluwer Academic Publishers, c1988
大学図書館所蔵 全6件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographies and index
内容説明・目次
内容説明
It has been recognized for many years that cancers originating in the breast and prostate gland are frequently 'endocrine-dependent. ' Traditional thera pies included surgical endocrine ablative procedures or pharmacologic hor mone administration, both designed to antagonize the stimulatory effects of sex steroid hormones. In the past decade, several new treatment strategies for these tumors have emerged from basic studies in reproductive biology and mechanisms of action of steroid hormones. In some instances, these new treatments have elimin ated or reduced the need for major surgical ablative procedures or for toxic hormone therapy. The clinical role for other new treatments has not yet been clearly defined, although exciting preliminary data from recent clinical trials are now available. Thus, an objective review of the current status of these new therapeutic approaches is of interest. In this volume we have attempted to provide an in-depth review of both basic and clinical research involving several new treatment strategies for breast and prostate cancer. The first three chapters summarize preclinical and clinical studies of the luteinizing hormone-releasing hormone analogues, which can be used effectively to induce 'medical castration. ' Chapters 4, 5, and 6 review the rationale and clinical use of the compounds known collec tively as the aromatase inhibitors, which can also be used to suppress sex steroid hormone levels. Antiestrogen mechanism of action and its clinical implications for the design of innovative treatment approaches is considered in chapters 7 and 8.
目次
1. Preclinical Studies and Antitumor Mechanism of Action of Luteinizing Hormone-Releasing Hormone Analogues.- 2. Luteinizing Hormone-Releasing Hormone Analogues in the Treatment of Prostate Cancer.- 3. Luteinizing Hormone-Releasing Hormone Agonists in the Treatment of Breast Cancer.- 4. Aromatase Inhibitors as New Endocrine Therapy for Breast Cancer.- 5. Clinical Use of Aromatase Inhibitors in the Treatment of Breast Cancer.- 6. Aminoglutethimide: Theoretical Considerations and Clinical Results in Advanced Prostate Cancer.- 7. Antiestrogen Therapy for Breast Cancer: Current Strategies and Future Prospects.- 8. Effects of Estrogens and Antiestrogens on Cell Proliferation: Implications for the Treatment of Breast Cancer.- 9. Flutamide and Other Antiandrogens in the Treatment of Advanced Prostatic Carcinoma.- 10. Progestational Agents in the Treatment of Breast Cancer.
「Nielsen BookData」 より